文献速递传染病防控与疫情报告卫生政策与健康促进

美国HIV暴露前预防用药的 uptake、依从性与持续性干预综述

Pre-exposure Prophylaxis Uptake, Adherence, and Persistence: A Narrative Review of Interventions in the U.S.
PubMed 文献 · Am J Prev Med · 2021-01-01

该叙述性综述梳理2017至2020年间20项研究,评估行为改变、技术辅助和替代给药策略对PrEP三个阶段的干预效果。随机对照数据支持3项行为干预和1项技术干预,替代给药策略前景可期但需更严谨设计。未来研究应覆盖所有高危人群并适配长效制剂。

要点

  • 随机对照数据支持3项行为改变干预和1项技术干预改善PrEP依从性。
  • 替代给药策略(药房、整合服务、家庭递送)前景可期但需更严谨研究。
  • 现有干预多聚焦男男性行为者,需覆盖非裔、拉美裔异性恋及注射吸毒者。

核心结论

  • PrEP在 uptake、依从性和持续性三阶段仍不理想,但行为、技术及替代给药干预已取得进展。

研究设计与样本

  • 叙述性综述分析2017至2020年间20项评估个体和结构层面干预的研究,并梳理20项在研试验。

主要发现

  • 多数已发表干预针对男男性行为者,仅3项评估女性(2项跨性别、1项顺性别)。
  • 随机对照数据支持3项行为改变干预和1项技术干预。
  • 替代给药策略(药房PrEP、服务整合、家庭递送)显示出前景但需更严谨设计。
  • 关于HIV风险与PrEP持续性对齐(预防有效依从)的数据有限。

临床怎么用

  • 可优先采用经随机对照验证的行为改变和技术干预提升PrEP依从性。
  • 探索药房、整合服务及家庭递送等替代策略以改善持续性。
  • 干预设计需覆盖非裔、拉美裔异性恋及注射吸毒者等高危群体。

局限性

  • 多数研究聚焦男男性行为者,其他高危群体证据不足。
  • 替代给药策略缺乏稳健研究设计。
  • 预防有效依从的相关数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Since 2012, HIV pre-exposure prophylaxis (PrEP) has been available to prevent HIV transmission; yet, uptake, adherence, and persistence to PrEP have been suboptimal. This narrative review examines the latest interventions and programs to improve all 3 stages of PrEP adherence and reviews ongoing studies to promote effective PrEP use. From 2017 to 2020, a total of 20 studies analyzed different individual- and structural-level approaches to increase PrEP adherence, including behavior change interventions, technology-based interventions (e.g., short message service messages and mobile applications), and alternate delivery strategies (e.g., pharmacy-based PrEP, integration with other services, and home delivery). Most published interventions involved men who have sex with men, although 3 assessed women (2 transgender, 1 cisgender). Randomized, controlled data support 3 behavioral change interventions and 1 technology-based intervention. Alternate delivery strategies seem promising, although more robust study designs are generally needed. In addition, data on the alignment of ongoing HIV risk and PrEP persistence (i.e., prevention-effective adherence) were limited. The authors also identified 20 ongoing studies that are promoting PrEP adherence. Future work should be inclusive of all at-risk groups in the U.S., including African American and Latinx heterosexual populations and people who inject drugs. Proven and promising approaches may work well in combination and may also need to be adapted with the introduction of long-acting pre-exposure prophylaxis formulations. Collectively, this body of work indicates considerable progress toward understanding the role PrEP adherence will play in Ending the HIV Epidemic in the U.S. that will be bolstered by the outcomes of ongoing trials.

来源:Am J Prev Med,查看原文。版权归原作者所有。

引用

  1. Garrison LE, Haberer JE. Pre-exposure Prophylaxis Uptake, Adherence, and Persistence: A Narrative Review of Interventions in the U.S. Am J Prev Med. 2021. PMID: 34686294. doi:10.1016/j.amepre.2021.04.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。